source
- Lilly-backed TRex Bio raises $117M in IPO as hypertension biotech Retension secures $45M listingTRex Bio, a biotech backed by Eli Lilly, completed its initial public offering, generating $116.7 million in gross proceeds. The company sold 8.3 million shares at $14 each, landing at the lower en…
- CBER Director Karim Mikhail Aims to Restore Stability After Turbulent Leadership ChangesThe FDA's Center for Biologics Evaluation and Research (CBER) is working to regain stability after a period of rapid leadership turnover. Karim Mikhail, who was confirmed as the permanent director…